Paxil Not for Kids
June 20 -- The FDA yesterday warned that children younger than 18 should not
take the antidepressant Paxil because of a possible increased risk of
"suicidal thinking and suicide attempts" associated with the drug.
This statement from the FDA came on the heels of a similar warning on June 10 by
British regulators. The drug is known as Seroxat in the UK.
Quote: "There is currently
no evidence that Paxil is effective in children or adolescents with MDD (major
depressive disorder), and Paxil is not
currently approved for use in children and adolescents." (FDA Statement)
Our Comment: In the US, the FDA permits physicians to prescribe
approved medications for other than their intended indications. This practice is
known as off-label use. Although there is practical merit in off-label use, the
current situation surrounding Paxil illustrates one of the dangers of off-label
drug usage.
For additional information please visit the following MedicineNet.com areas:
Barbara K. Hecht,
Ph.D.
Frederick Hecht, M.D.
Medical Editors, MedicineNet.com
FDA Statement Regarding the
Anti-Depressant Paxil for Pediatric Population
|
ADVISORY:
DESPITE THE NEW POSSIBLE SAFETY CONCERNS ABOUT USE OF PAXIL IN CHILDREN,
IT IS ESSENTIAL THAT PATIENTS TAKING PAXIL
(paroxetine hydrochloride) DO NOT SUDDENLY DISCONTINUE USE OF THE DRUG.
ANY CHANGES MUST TAKE PLACE UNDER MEDICAL SUPERVISION. |
The Food and Drug Administration (FDA) said today it is
reviewing reports of a possible increased risk of suicidal thinking and suicide
attempts in children and adolescents under the age of 18 treated with the drug
Paxil for major depressive disorder (MDD). Although the FDA has not completed
its evaluation of the new safety data, FDA is recommending that Paxil not be used in children and
adolescents for the treatment of MDD. There is currently no evidence that Paxil
is effective in children or adolescents with MDD, and Paxil is not currently
approved for use in children and adolescents. Other approved treatment options
are available for depression in children.
Paxil is approved for use in adults for the treatment of
Obsessive Compulsive Disorder (OCD), MDD, Panic Disorder, Social Anxiety Disorder (SAD), Generalized
Anxiety Disorder, and Post-traumatic
Stress Disorder. There is no evidence that
Paxil is associated with an increased risk of suicidal thinking in adults.
Three well-controlled trials in pediatric patients with
MDD failed to show that the drug was more effective than placebo. The new safety information that
is currently under review was derived from trials of Paxil in pediatric
patients. Following its review of the same data, the UK Department of Health
issued a Press Release on June 10 stating that paroxetine (brand name Seroxat in
the UK) must not be used to treat children and teenagers under the age of 18
years for depressive illness because UK authorities have concluded that there is
an increase in the rate of self harm and potentially suicidal behavior in this
age group, when paroxetine is used for depressive illness.
FDA advises that caretakers of pediatric patients
already receiving treatment with Paxil for MDD talk to their doctor before stopping use of the drug.
Patients should not discontinue use of Paxil without first consulting their
physicians, and it is important that Paxil not be abruptly discontinued.
More information about today's statement is available at http://www.fda.gov/cder/drug/infopage/paxil/default.htm.
Source: FDA Talkpaper # T03-43, June 19, 2003
Last Editorial Review: 6/20/2003